Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Summary
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immutep : Receives A$3.4 million R&D Tax Incentive from French Government (Form 6-K)

09/29/2021 | 06:52am EST

Immutep Receives A$3.4 million R&D Tax Incentive from French Government

SYDNEY, AUSTRALIA - 29 September 2021 -Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €2,126,617 (~ A$3,430,952) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d'Impôt Recherche scheme (CIR).

The "Crédit d'Impôt Recherche" (CIR), meaning "Research Tax Credit", is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.

Immutep qualifies to receive CIR tax incentive through its subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory at Châtenay-Malabry in southwestern Paris. The cash payment is provided in respect of expenditure incurred on eligible R&D activities conducted in European Union in the 2020 calendar year. Immutep also qualifies for cash rebates from the Australian Federal Government's R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in Australia. In April 2021, the Company received a A$1,155,055 cash rebate in respect of expenditure incurred on eligible R&D activities conducted in the 2020 fiscal year.

The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep's current lead product candidate is eftilagimod alpha ("efti" or "IMP321"), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep's large pharmaceutical partners.

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889

Further information can be found on the Company's website www.immutep.com or by contacting:

Australian Investors/Media:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:

Tim McCarthy, LifeSci Advisors

+1 (212) 915.2564; tim@lifesciadvisors.com

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889

Disclaimer

Immutep Ltd. published this content on 29 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 September 2021 10:51:01 UTC.


ę Publicnow 2021
All news about IMMUTEP LIMITED
12/05IMMUTEP : Change in substantial holding
PU
12/03IMMUTEP : REPORTS GOOD SAFETY FROM FIRST FIVE PATIENTS IN TRIPLE COMBINATION THERAPY EFTI ..
PU
12/02Immutep Doses First Five Patients in Study of Triple Combination Cancer Treatment, Find..
MT
12/01IMMUTEP : Reports Good Safety from First Five Patients in Triple Combination Therapy Efti ..
PU
12/01Immutep Limited Reports Good Safety from First Five Patients in the INSIGHT-003 study
CI
12/01IMMUTEP : Application for quotation of securities - IMM
PU
11/29IMMUTEP : Notification regarding unquoted securities - IMM
PU
11/25IMMUTEP : Results of Annual General Meeting
PU
11/25IMMUTEP : AGM 2021 - Chairman's Address
PU
11/25IMMUTEP : AGM 2021 - CEO's presentation
PU
More news
Analyst Recommendations on IMMUTEP LIMITED
More recommendations
Financials
Sales 2022 2,63 M 1,85 M 1,85 M
Net income 2022 -37,8 M -26,7 M -26,7 M
Net cash 2022 78,5 M 55,3 M 55,3 M
P/E ratio 2022 -6,93x
Yield 2022 -
Capitalization 376 M 265 M 265 M
EV / Sales 2022 113x
EV / Sales 2023 20,1x
Nbr of Employees -
Free-Float 85,2%
Chart IMMUTEP LIMITED
Duration : Period :
Immutep Limited Technical Analysis Chart | IMM | AU000000IMM6 | MarketScreener
Technical analysis trends IMMUTEP LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,44 AUD
Average target price 1,17 AUD
Spread / Average Target 166%
EPS Revisions
Managers and Directors
Marc Voigt Chief Executive Officer, CFO & Executive Director
David Fang Finance Director & Assistant Secretary
Russell John Howard Non-Executive Chairman
FrÚdÚric Triebel Chief Scientific & Medical Officer
Deanne Miller COO, Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
IMMUTEP LIMITED6.02%279
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-42.48%24 298